EIGR

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5

Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy® (lonafarnib)

Eiger Bio's Avexitide Reduces Glucose Infusion Requirements To Maintain Normal Glucose Levels In Neonates, Infants

Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session

Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

Eiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory on Q1 2021 Results - Earnings Call Transcript